News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celsion Corporation (CLN) Reports Year End 2013 Financial Results And Provides Business Update


3/13/2014 6:37:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAWRENCEVILLE, N.J., March 13, 2014 /PRNewswire/ -- Celsion Corporation (CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at Yahoo Finance

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES